WINRHO SDF KIT

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

ANTI-D (RH) IMMUNOGLOBULIN (HUMAN)

可用日期:

APTEVO BIOTHERAPEUTICS LLC

ATC代码:

J06BB01

INN（国际名称）:

ANTI-D (RH) IMMUNOGLOBULIN

剂量:

600UNIT

药物剂型:

KIT

组成:

ANTI-D (RH) IMMUNOGLOBULIN (HUMAN) 600UNIT

给药途径:

INTRAMUSCULAR

每包单位数:

120MCG-STERILE DILUENT 8.5ML

处方类型:

Schedule D

治疗领域:

SERUMS

產品總結:

Active ingredient group (AIG) number: 0106269002; AHFS:

授权状态:

CANCELLED POST MARKET

授权日期:

2016-07-15

产品特点

_WinRho® SDF Product Monograph _
_Page 1 of 43 _
_ _
PRODUCT MONOGRAPH
WINRHO
® SDF
Rh
o
(D) Immune Globulin (Human) for injection
Lyophilized: 600 IU (120 µg), 1500 IU (300 µg), 5000 IU (1000 µg)
Liquid: 600 IU (120 µg), 1500 IU (300 µg), 2500 IU (500 µg), 5000
IU (1000 µg), 15 000 IU
(3000 µg)
World Health Organization (WHO) Anti-D Immune Globulin (Human) 2
nd
International
Standard
Passive Immunizing Agent
Aptevo BioTherapeutics LLC,
Berwyn PA, 19312, USA
Distributor (in Canada): Cangene Corp.,
a subsidiary of Emergent BioSolutions Inc.
Winnipeg, MB, R3T 5Y3
Submission Control #: 194264
Date of Authorization: May 20, 2016
_WinRho® SDF Product Monograph _
_Page 2 of 43 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
DESCRIPTION....................................................................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................4
CONTRAINDICATIONS
...................................................................................................5
WARNINGS AND PRECAUTIONS
..................................................................................6
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................17
DOSAGE AND ADMINISTRATION
..............................................................................18
OVERDOSAGE
................................................................................................................22
ACTION AND CLINICAL PHARMACOLOGY
............................................................22
STORAGE AND STABILITY
......................................................................................